TABLE 2.
Infection characteristics
| Characteristica | Valuesb for: |
|
|---|---|---|
| Total cohort (n = 259) | Patients with MDR Pseudomonas aeruginosa (n = 226) | |
| Hospital-acquired infection | 161 (62.2) | 142 (62.8) |
| Hours from admission to culture collection | 111 (21–376) | 129 (21–384) |
| Infection source | ||
| Primary bacteremia | 4 (1.5) | 4 (1.8) |
| Respiratory | 163 (62.9) | 149 (65.9) |
| Ventilator-associated pneumonia | 96/163 (58.9) | 89/149 (59.7) |
| Intra-abdominal | 18 (6.9) | 11 (4.9) |
| Skin and soft tissue | 28 (10.8) | 27 (11.9) |
| Osteoarticular | 15 (5.8) | 10 (4.4) |
| Urine | 26 (10.0) | 21 (9.3) |
| Prosthetic device | 1 (0.4) | 1 (0.4) |
| Intravenous catheter | 2 (0.8) | 2 (0.9) |
| Other | 1 (0.4) | 1 (0.4) |
| Positive blood cultures | 8 (3.1) | 8 (3.5) |
| Enterobacterales | ||
| Klebsiella pneumonia | 13 (5.0) | 10 (4.4) |
| Ceftriaxone resistant | 10/13 (76.9) | 8/10 (80) |
| K. oxytoca | 4 (1.5) | 2 (0.9) |
| Escherichia coli | 17 (6.6) | 10 (4.4) |
| Ceftriaxone resistant | 11/17 (64.7) | 7/10 (70) |
| Enterobacter spp. | 5 (1.9) | 4 (1.8) |
| Proteus mirabilis | 14 (5.4) | 13 (5.8) |
| Ceftriaxone resistant | 2/14 (14.3) | 2/13 (15.4) |
| Citrobacter spp. | 3 (1.2) | 3 (1.3) |
| Serratia marcescens | 5 (1.9) | 5 (2.2) |
| Providentia stuarti | 13 (5.0) | 13 (5.8) |
| Ceftriaxone resistant | 6/13 (46.2) | 5/13 (38.5) |
| Morganella morganii | 1 (0.4) | 1 (0.4) |
| Pseudomonas spp. | 239 (92.3) | |
| P. aeruginosa | 236 (91.1) | |
| MDR | 226 (87.3) | |
| XDR | 89 (34.4) | 89 (39.4) |
| Acinetobacter spp. | 12 (4.6) | 10 (4.4) |
| Stenotrophomonas maltophilia | 6 (2.3) | 6 (2.7) |
| Achromobacter xylosoxidans | 3 (1.2) | 3 (1.3) |
| Gram-positive | 49 (18.9) | 42 (18.6) |
| Polymicrobial infection | 91 (35.1) | 82 (36.3) |
| P. aeruginosa C/T MIC (mg/liter) (n) | 126 | 125 |
| MIC50 | 1 | 1 |
| MIC90 | 4 | 8 |
a
MDR, multidrug resistant; XDR, extensively drug resistant.
b
All values represent n (%) or median (interquartile range).